You are here

NECTAGEN INC

Company Information
Address
2002 W 39TH AVE
KANSAS CITY, KS 66103-2943
United States



Information

UEI: KAFMLCY56WM3

# of Employees: 4


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Development of an Orally Available Therapeutic for Neutralizing C. difficile Toxin B

    Amount: $274,500.00

    Infection with the bacterium C. difficile is the most common and increasingly prevalent cause of diarrhea. In the United States, cases of C. difficile infection (CDI) are estimated to number 500,000 a ...

    STTRPhase I2023Department of Health and Human Services National Institutes of Health
  2. Development of DNA-Labeled Antibody Mimetics as Low-Cost, High-Performance Reagents for Single Cell Analysis of Membrane Proteins

    Amount: $252,484.00

    Averaging signals over a population of cells often misses biologically relevant variation among single cells. New approaches are emerging with the power to identify differences between individual cell ...

    SBIRPhase I2021Department of Health and Human Services National Institutes of Health
  3. Development of Enzyme Replacement Therapy for Complement C2-Deficiency

    Amount: $150,000.00

    The goal of this Phase I SBIR project is to develop a scalable method of Cpurification for use in Creplacement therapy based on a novel immunoaffinity chromatography resinDeficiency of complement CC D ...

    SBIRPhase I2019Department of Health and Human Services National Institutes of Health
  4. Generation of High Resolution Antibody Mimetics to Improve the Visualization of Subcellular Structures by Super Resolution Microscopy

    Amount: $150,000.00

    The goal of this Phase I SBIR project is to develop a set of high resolution antibody mimeticsnanoCLAMPsoptimized for super resolution imaging of a broad range of subcellular structuresAdvances in sup ...

    SBIRPhase I2018Department of Health and Human Services National Institutes of Health
  5. Affinity reagents for the sub-fractionation of specific exosomal populations

    Amount: $149,931.00

    The goal of this Phase I SBIR project is to develop affinity reagents useful for the sub fractionation of specific exosomal populationsBecause exosomal makeup and cargo reflect the typedevelopmental s ...

    SBIRPhase I2018Department of Health and Human Services National Institutes of Health
  6. SBIR TOPIC 294 PHASE I- DEVELOPMENT OF GLYCOSYLATION- SPECIFIC RESEARCH

    Amount: $149,993.00

    The function of many cancer related proteins is modulated by modifications such as phosphorylation and glycosylation. The development of antibodies that recognize site-specific phosphorylation has va ...

    SBIRPhase I2011Department of Health and Human Services National Institutes of Health
  7. High-Throughput Low Cost Production of Chromatin-Immunoprecipitation-Grade Antib

    Amount: $97,500.00

    DESCRIPTION (provided by applicant): Identifying the regulatory regions of the genome is critical for understanding the regulatory networks underlying human development and disease. Chromatin immunop ...

    SBIRPhase I2010Department of Health and Human Services National Institutes of Health
  8. DEVELOPMENT OF ALTERNATIVE AFFINITY CAPTURE REAGENTS FOR CANCE

    Amount: $149,857.00

    Many of the antibodies produced for cancer research are poorly characterized, exhibit suboptimal affinity or selectivity, and are time-consuming and expensive to produce. Alternative affinity capture ...

    SBIRPhase I2010Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government